Home > Result Summaries: Compounds > Combined Diphtheria, Tetanus, Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), Inactivated Polio Vaccine Result Summaries: Combined Diphtheria, Tetanus, Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), Inactivated Polio Vaccine GSKStudy ID Phase Title Summary (Download) 110478 Phase 4 Immunogenicity and reactogenicity study of a new formulation of GSK Biologicals' DTPa-HBV-IPV/Hib vaccine administered as a booster dose to 18-23 months old children (0 citation(s)) 217744/001 Phase 3 Open randomised clinical study to evaluate the immunogenicity and reactogenicity of SmithKline Beecham Biologicals’ combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine in comparison to SmithKline Beecham Biologicals' combined diphtheria, tetanus, acellu ... (0 citation(s)) 217744/002 Phase 3 Open clinical study to evaluate the immunogenicity and reactogenicity of SmithKline Beecham Biologicals' combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine. The vaccines will be administered as primary vaccinations to healthy infants at 2, 4, and 6 mon ... (0 citation(s)) 217744/004 Phase 3 Open clinical study to evaluate the immunogenicity and reactogenicity of SmithKline Beecham Biologicals combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine, co-administered with commercially available Hib vaccine as two separate injections in opposite l ... (0 citation(s)) 217744/010 Phase 3 Open clinical study to evaluate the immunogenicity and reactogenicity of SB Biologicals' DTPa-HBV-IPV vaccine, co-administered with SB Biologicals' Hib vaccine as two separate injections in opposite limbs (0 citation(s)) 217744/011 Phase 3 Randomised clinical study to assess the safety and reactogenicity of SB Biologicals' DTPa-HBV-IPV vaccine, when co-administered with Hib vaccine in two concomitant injections into opposite limbs, as a primary vaccination course to healthy infants at the age of 3, 4 and 5 months (1 citation(s)) 217744/012 Phase 3 Randomised clinical study to assess the immunogenicity and reactogenicity of SB Biologicals' DTPa-HBV-IPV vaccine, when co-administered with Hib vaccine in two concomitant injections into opposite limbs, as a primary vaccination course to healthy infants at the age of 3, 4½ and 6 months (1 citation(s)) 217744/015 Phase 2 An open study of the safety and immunogenicity of DTPa-HBV-IPV vaccine administered as a three dose series or in a sequential IPV/OPV schedule at 2, 4, and 6 months of age (1 citation(s)) 217744/028 Phase 3 Study to assess the safety and reactogenicity of SB Bios DTPa vaccine, co-administered with commercial Hib vaccine as compared to SB Bios' DTPa vaccine-SB Bios' DTPa-IPV vaccine each time mixed with SB Bios’ Hib vaccine, and to SB Bios’ DTPa-HBV-IPV vaccine co-administered with SB Bios’ Hib vaccine (1 citation(s)) 217744/030 Phase 3 A phase III open randomised primary vaccination study of three doses of SB Biologicals’ DTPa-HBV-IPV vaccine co-administered with SB Biologicals’ Hib vaccine into opposite limbs, compared to commercially available DTPw-IPV/Hib vaccine co-administered with hepatitis B vaccine, in healthy children (1 citation(s)) 217744/061 Phase 2 Phase II, single-blinded, randomized comparative study of the safety and immunogenicity of a booster dose of SB Bios' DTPa-HBV-IPV vaccine compared with Infanrix when both vaccines are co-administered with OmniHIB between 15 and 18 months of age after primary immunization at the age of 2, 4 and 6 (1 citation(s)) 217744/077 Phase 3 A phase III, double-blind, randomized, multicenter primary vaccination study to bridge the DTPa-HBV-IPV vaccine manufactured according to the large scale manufacturing process with the DTPa-HBV-IPV vaccine manufactured by the small scale manufacturing process when administered intramuscularly to ... (1 citation(s)) 217744/084 Phase 3 A phase III, open labeled, randomized, multicenter, clinical study of the safety of a primary series of GlaxoSmithKline Biologicals' (GSK Biologicals') DTaP-HepB-IPV combined candidate vaccine coadministered with HibTITER® and Prevnar® to healthy infants at 2, 4, and 6 months of age as compared ... (1 citation(s)) 217744/085 Phase 3 A phase III, open labeled, randomized, multicenter, clinical study of the safety and immunogenicity of a primary series of GlaxoSmithKline Biologicals' (GSK Biologicals') DTaP-HepB-IPV candidate vaccine coadministered with HibTITER® and Prevnar® to healthy infants at 2, 4, and 6 months of age as ... (1 citation(s)) 217744/097 Phase 3 Study to assess immunogenicity and reactogenicity of three doses of GSK Bio’s combined Hib-MenC vaccine co-admind with GSK Bio’s DTPa-HBV-IPV vaccine and of two doses of Baxters meningococcal C conjugate vaccine co-admind with GSK Bio’s DTPa-HBV-IPV/Hib vaccine (5 citation(s)) 217744/099 Phase 2 A phase II, randomized, partially blinded clinical trial to evaluate the immunogenicity and reactogenicity of an investigational vaccine regimen of GSK Biologicals as compared to GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix™ hexa) and to the concomitant administration of GSK Biologicals’ ... (0 citation(s)) 347414/016 Phase 2 A phase II, single-blind, randomised, controlled, multicentre study to evaluate the safety, reactogenicity and immunogenicity of two experimental formulations versus a licensed Haemophilus influenzae type b (Hib) conjugate vaccine (Hiberix™ or HibTiter™) administered as primary vaccination to i ... (0 citation(s)) 347414/028 Phase 2 A randomized, controlled, open, phase-II clinical study to evaluate the safety and immunogenicity of an experimental formulation extemporaneously mixed with SB Bios' Haemophilus influenzae type b (Hib) vaccine, administered as a booster dose with DTPa-HBV-IPV to healthy children 12 to 18 months old. (0 citation(s)) 711202/001 Phase 2 Evaluate immunogenicity, reactogenicity, safety of GSK Biologicals’ MenC-TT vaccine (2 formulations) given with Infanrix hexa® + GSK Biologicals’ Hib MenC-TT vaccine (2 formulations) given with Infanrix penta® to infants in mths 3,4,5 of life (1 citation(s)) 811936/001 Phase 2 Phase 2, open, randomized, controlled study to demonstrate the non-inferiority of the meningoc serogroup C immune resp and the superiority of the Hib immune resp of GSK Bios’ Haemophilus influenzae type b-meningoc C-TT conjugate vac admin with Infanrix™ penta versus Meningitec™ admin with Infanrix™ (0 citation(s)) 811936/003 Phase 3 A phase 3, open, randomized, controlled, multicentre study to evaluate the safety and reactogenicity profile of GSK Bios’ Haemophilus influenzae type b–meningococcal serogroup C conjugate candidate vac given with GSK Bios’ diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (0 citation(s))
